ES2067546T3 - Derivado de oxaspiro(2,5)octano. - Google Patents
Derivado de oxaspiro(2,5)octano.Info
- Publication number
- ES2067546T3 ES2067546T3 ES89308113T ES89308113T ES2067546T3 ES 2067546 T3 ES2067546 T3 ES 2067546T3 ES 89308113 T ES89308113 T ES 89308113T ES 89308113 T ES89308113 T ES 89308113T ES 2067546 T3 ES2067546 T3 ES 2067546T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- alkylcarbamoyl
- formula
- radical
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 title abstract 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical class O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- KKFDJZZADQONDE-UHFFFAOYSA-N (hydridonitrato)hydroxidocarbon(.) Chemical class O[C]=N KKFDJZZADQONDE-UHFFFAOYSA-N 0.000 abstract 1
- VUEWYZJJYGPJDC-UHFFFAOYSA-N 1-oxaspiro[2.5]octane Chemical class C1OC11CCCCC1 VUEWYZJJYGPJDC-UHFFFAOYSA-N 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- -1 HALOARILCARBAMOILO Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- CBCIHIVRDWLAME-UHFFFAOYSA-N hexanitrodiphenylamine Chemical class [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O CBCIHIVRDWLAME-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000003068 rheumatic fever Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/34—Compounds containing oxirane rings with hydrocarbon radicals, substituted by sulphur, selenium or tellurium atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Dental Preparations (AREA)
- Photoreceptors In Electrophotography (AREA)
- Polyesters Or Polycarbonates (AREA)
- Cereal-Derived Products (AREA)
- Seasonings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
UN DERIVADO DE OXAESPIRO[2,5]OCTANO DE FORMULA (I), DONDE R1 ES CARBAMOILO, ALQUILCARBAMOILO INFERIOR, HIDROXIALQUILCARBAMOILO INFERIOR, ALCOXIALQUILCARBAMOILO INFERIOR, ALQUILTIOINFERIOR ALQUILCARBAMOILO INFERIOR, ALCOXICARBONILO INFERIOR ALQUILCARBAMOILO INFERIOR, ALQUILCARBAMOILOXI INFERIOR ALQUILCARBAMOILO INFERIOR, DIALQUILCARBAMOILO INFERIOR, N-(HIDROXIALQUIL INFERIOR) ALQUILCARBAMOILO INFERIOR, N-(HIDROXIALQUILO INFERIOR) ALQUILCABAMOILOXI INFERIOR ALQUILCARBAMOILO INFERIOR, ALQUILCARBAMOILOXI INFERIOR ALQUENOILO INFERIOR, N-(HETEROCICLIL CARBONILOXI ALQUIL INFERIOR) ALQUIL CARBAMOILO INFERIOR, CICLOALQUILCARBAMOILO INFERIOR, ARILCARBAMOILO, HALOARILCARBAMOILO, CARBAMOILO PROTEGIDO, ALQUILTIOCARBAMOILO INFERIOR, HETEROCICLILCARBAMOILO, ARALQUENOILO INFERIOR, ALCOXICARBONILO INFERIOR, HETEROCICLILCARBONILO QUE PUEDE TENER ALQUILO INFERIOR, HIDROXI, HIDROXIALQUILO INFERIOR, ALCOXI INFERIOR ALQUILO INFERIOR, O ALCOXICARBONILO INFERIOR, ALQUILO INFERIOR, CARBOXIALQUILO INFERIOR, CARBOXIALQUILO INFERIOR PROTEGIDO, ARALQUIL INFERIOR QUE PUEDE TENER HALOGENO O ALCOXI INFERIOR, HETEROCICLILALQUILO INFERIOR, ALQUILCARBAMOIL ALQUILO INFERIOR, HIDROXIALQUENILOXI INFERIOR, O DIACILOXIALQUENOILO INFERIOR; R2 ES ALCOXI INFERIOR; Y R3 ES 2-(6-METIL-2,3-OXA)-HEPTEN-5-ILO, EL RADICAL DE FORMULA: (FIG. A), DONDE R6 ES UN CARBOXI PROTEGIDO, EL RADICAL DE FORMULA: (FIG. B), DONDE R6 ES UN CARBOXI PROTEGIDO; 2-(2,3-OXA)HEXILO; EL RADICAL DE FORMULA; (FIG. C), DONDE R7 ES UN CARBOXI ALQUILO INFERIOR PROTEGIDO O UN ALQUILO INFERIOR QUE PUEDE TENER H; O UN RADICAL DE FORMULA: (FIG. D), DONDE R6 ES ACILO, O SUS SALES FARMACEUTICAMENTE ACEPTABLES. TAMBIEN SE DESCRIBE UN PROCEDIMIENTO PARA PREPARAR EL DERIVADO DE OXAESPIRO[2,5]OCTANO, JUNTO CON UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE COMO INGREDIENTE ACTIVO. LOS COMPUESTOS TIENEN ACTIVIDAD INHIBIDORA DE ANGIOGENESIS, Y SON POR ELLO UTILES EN EL TRATAMIENTO DE, POR EJEMPLO, TUMORES, ARTRITIS REUMATICA, RETINOPATIA DIABETICA Y SORIASIS.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888819258A GB8819258D0 (en) | 1988-08-12 | 1988-08-12 | Oxaspiro(2 5)octane compound |
| GB888819256A GB8819256D0 (en) | 1988-08-12 | 1988-08-12 | Oxaspiro(2 5)octane derivative |
| GB898908029A GB8908029D0 (en) | 1989-04-10 | 1989-04-10 | Oxaspriro(2,5)octane derivative |
| GB898909794A GB8909794D0 (en) | 1989-04-28 | 1989-04-28 | Cyclohexane derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2067546T3 true ES2067546T3 (es) | 1995-04-01 |
Family
ID=27450157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES89308113T Expired - Lifetime ES2067546T3 (es) | 1988-08-12 | 1989-08-09 | Derivado de oxaspiro(2,5)octano. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US5789405A (es) |
| EP (1) | EP0354787B1 (es) |
| JP (2) | JP2773275B2 (es) |
| KR (1) | KR0130765B1 (es) |
| CN (1) | CN1051703C (es) |
| AT (1) | ATE118490T1 (es) |
| AU (1) | AU632056B2 (es) |
| CA (1) | CA1340291C (es) |
| DE (1) | DE68921114T2 (es) |
| DK (1) | DK171987B1 (es) |
| ES (1) | ES2067546T3 (es) |
| FI (1) | FI97805C (es) |
| GR (1) | GR3015382T3 (es) |
| HU (1) | HU211569A9 (es) |
| IE (1) | IE66923B1 (es) |
| IL (1) | IL91250A (es) |
| NO (1) | NO173236C (es) |
| PH (1) | PH26256A (es) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH26256A (en) * | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| JPH0660095B2 (ja) * | 1988-09-01 | 1994-08-10 | 武田薬品工業株式会社 | 血管新生阻害剤 |
| JPH0660168B2 (ja) * | 1988-09-01 | 1994-08-10 | 武田薬品工業株式会社 | ０―置換フマギロール誘導体 |
| ES2099064T3 (es) * | 1988-09-01 | 1997-05-16 | Takeda Chemical Industries Ltd | Derivados de fumagillol. |
| ATE87623T1 (de) * | 1989-03-06 | 1993-04-15 | Takeda Chemical Industries Ltd | 6-epifumagillole, ihre herstellung und ihre verwendung. |
| US5290807A (en) * | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
| US6017954A (en) * | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| EP0415294A3 (en) * | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
| TW282399B (es) * | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
| EP1004318A3 (en) * | 1991-06-21 | 2002-08-07 | Takeda Chemical Industries, Ltd. | Cyclodextrin composition |
| WO1993005777A1 (fr) * | 1991-09-18 | 1993-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Preparation transoculaire |
| DE69311278T2 (de) * | 1992-12-16 | 1997-10-30 | Takeda Chemical Industries Ltd | Stabile pharmazeutische Zubereitung mit Fumagillolderivaten |
| US5710148A (en) * | 1995-03-06 | 1998-01-20 | Senju Pharmaceuticals Co., Ltd. | Corneal opacification inhibitory composition |
| FR2733499B1 (fr) * | 1995-04-27 | 1997-05-30 | Adir | Nouvelles tetrahydropyrano(3,2-d)oxazolones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2733498B1 (fr) * | 1995-04-27 | 1997-05-30 | Adir | Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US5719167A (en) * | 1995-08-07 | 1998-02-17 | Alcon Laboratories, Inc. | Angiostatic compounds |
| US5798356A (en) * | 1995-08-07 | 1998-08-25 | Alcon Laboratories, Inc. | Angiostatic compounds |
| EP0867180A4 (en) * | 1995-10-11 | 1999-09-15 | Fujisawa Pharmaceutical Co | VASCULAR PERMEATION INHIBITOR |
| US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
| WO1999061432A1 (en) * | 1998-05-12 | 1999-12-02 | Biochem Pharma Inc. | Fumagillin analogs and their use as angiogenesis inhibitors |
| KR100357541B1 (ko) * | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
| KR100357542B1 (ko) * | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| US7105482B2 (en) * | 2000-11-01 | 2006-09-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| PL366216A1 (en) * | 2000-11-01 | 2005-01-24 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US6919307B2 (en) * | 2000-11-01 | 2005-07-19 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| EP1699812A2 (en) * | 2003-12-29 | 2006-09-13 | Praecis Pharmaceuticals Inc. | Inhibitors of methionine aminopeptidase-2 and uses thereof |
| US7931261B2 (en) * | 2006-01-24 | 2011-04-26 | Goss International Americas, Inc. | Signature hopper with lap straightening device |
| CN101990441A (zh) | 2007-11-28 | 2011-03-23 | 默萨那治疗学股份有限公司 | 生物相容的生物可降解的烟曲霉素类似物轭合物 |
| US8865746B2 (en) * | 2008-07-18 | 2014-10-21 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| CN102448469A (zh) | 2009-05-28 | 2012-05-09 | 摩萨纳医疗有限公司 | 包括具有可变的释放速率的连接物的聚缩醛(酮)-药物共轭物 |
| EP2486004B1 (en) | 2009-10-09 | 2017-05-03 | Zafgen, Inc. | Sulphone compounds for use in the treatment of obesity |
| US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
| AU2011204267B2 (en) | 2010-01-08 | 2015-12-03 | Zafgen Corporation | Fumagillol type compounds and methods of making and using same |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| CN103249735B (zh) | 2010-07-22 | 2016-04-06 | 扎夫根股份有限公司 | 三环化合物及其制备和使用方法 |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| WO2012075020A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol |
| KR20140006888A (ko) | 2011-01-26 | 2014-01-16 | 자프겐 인크. | 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법 |
| CN103534244B (zh) | 2011-03-08 | 2016-10-12 | 扎夫根股份有限公司 | 氧杂螺[2.5]辛烷衍生物及类似物 |
| AU2012253759B2 (en) | 2011-05-06 | 2016-01-21 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| CA2835261C (en) | 2011-05-06 | 2019-06-04 | Zafgen, Inc. | Partially saturated tricyclic compounds and methods of making and using same |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| CA2837840C (en) | 2011-06-10 | 2020-08-04 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
| MX2014008706A (es) | 2012-01-18 | 2015-03-05 | Zafgen Inc | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. |
| JP2015509102A (ja) | 2012-01-18 | 2015-03-26 | ザフゲン，インコーポレイテッド | 三環式スルホン化合物並びにその作製および使用方法 |
| US9260419B2 (en) | 2012-05-07 | 2016-02-16 | Zafgen, Inc. | Polymorphic salt of a metap-2 inhibitor and methods of making and using same |
| AU2013259617A1 (en) | 2012-05-08 | 2014-11-27 | Zafgen, Inc. | Treating hypothalamic obesity with MetAP2 inhibitors |
| MX356755B (es) * | 2012-05-09 | 2018-06-11 | Zafgen Inc | Compuestos de tipo fumagilol y metodos para su elaboración y uso. |
| JP2015536981A (ja) | 2012-11-05 | 2015-12-24 | ザフゲン，インコーポレイテッド | 三環式化合物ならびにその製造および使用方法 |
| NZ707773A (en) | 2012-11-05 | 2019-05-31 | Zafgen Inc | Methods of treating liver diseases |
| BR112015010223A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | compostos tricíclicos para o uso no tratamento e/ou controle de obesidade |
| CA2892863C (en) | 2012-12-10 | 2022-03-15 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
| EP2931316B1 (en) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| CN105228610A (zh) | 2013-03-14 | 2016-01-06 | 扎夫根股份有限公司 | 治疗肾疾病和其它病症的方法 |
| KR102087850B1 (ko) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| KR102572149B1 (ko) | 2013-10-11 | 2023-08-30 | 아사나 바이오사이언시스 엘엘씨 | 단백질-폴리머-약물 접합체 |
| TW201636342A (zh) | 2014-12-19 | 2016-10-16 | 武田藥品工業有限公司 | 煙黴醇衍生物 |
| AR105671A1 (es) * | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| US10772971B2 (en) | 2017-06-22 | 2020-09-15 | Mersana Therpeutics, Inc. | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates |
| CN108530375B (zh) * | 2018-05-29 | 2020-04-21 | 南京药石科技股份有限公司 | 4-氧杂-7-氮杂螺[2.5]辛烷或其盐的中间体及制备方法 |
| MX2021004906A (es) | 2018-10-29 | 2021-09-10 | Mersana Therapeutics Inc | Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos. |
| US20250129033A1 (en) * | 2022-02-16 | 2025-04-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Metap2 inhibitors and uses thereof |
| CN119836306A (zh) | 2022-07-15 | 2025-04-15 | 费恩治疗有限公司 | 与cdcp1结合的抗体药物缀合物和其用途 |
| WO2024040009A2 (en) * | 2022-08-17 | 2024-02-22 | Primetime Life Sciences, Llc | Inhibitors of methionine aminopeptidase-2 and methods of preparation and uses thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0629278B2 (ja) * | 1985-06-26 | 1994-04-20 | 藤沢薬品工業株式会社 | オキサスピロオクタン化合物 |
| PH26256A (en) * | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| JPH0660168B2 (ja) * | 1988-09-01 | 1994-08-10 | 武田薬品工業株式会社 | ０―置換フマギロール誘導体 |
| ES2099064T3 (es) * | 1988-09-01 | 1997-05-16 | Takeda Chemical Industries Ltd | Derivados de fumagillol. |
| KR0141692B1 (ko) * | 1988-09-01 | 1998-06-01 | 우메모또 요시마사 | 맥관 형성 억제제 |
| ATE87623T1 (de) * | 1989-03-06 | 1993-04-15 | Takeda Chemical Industries Ltd | 6-epifumagillole, ihre herstellung und ihre verwendung. |
-
1989
- 1989-08-01 PH PH39029A patent/PH26256A/en unknown
- 1989-08-02 IE IE250589A patent/IE66923B1/en not_active IP Right Cessation
- 1989-08-07 JP JP1204257A patent/JP2773275B2/ja not_active Expired - Lifetime
- 1989-08-08 IL IL9125089A patent/IL91250A/en not_active IP Right Cessation
- 1989-08-09 DE DE68921114T patent/DE68921114T2/de not_active Expired - Fee Related
- 1989-08-09 EP EP89308113A patent/EP0354787B1/en not_active Expired - Lifetime
- 1989-08-09 ES ES89308113T patent/ES2067546T3/es not_active Expired - Lifetime
- 1989-08-09 DK DK390989A patent/DK171987B1/da not_active IP Right Cessation
- 1989-08-09 AT AT89308113T patent/ATE118490T1/de not_active IP Right Cessation
- 1989-08-09 AU AU39453/89A patent/AU632056B2/en not_active Ceased
- 1989-08-10 CA CA000607998A patent/CA1340291C/en not_active Expired - Fee Related
- 1989-08-11 NO NO893235A patent/NO173236C/no unknown
- 1989-08-11 KR KR1019890011591A patent/KR0130765B1/ko not_active Expired - Fee Related
- 1989-08-11 CN CN93104924A patent/CN1051703C/zh not_active Expired - Fee Related
- 1989-08-11 FI FI893794A patent/FI97805C/fi not_active IP Right Cessation
-
1991
- 1991-06-05 US US07/711,420 patent/US5789405A/en not_active Expired - Fee Related
-
1994
- 1994-08-05 US US08/287,589 patent/US5767293A/en not_active Expired - Fee Related
-
1995
- 1995-03-13 GR GR950400533T patent/GR3015382T3/el unknown
- 1995-06-22 HU HU95P/P00365P patent/HU211569A9/hu unknown
-
1996
- 1996-03-25 JP JP8067849A patent/JP2970524B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK390989D0 (da) | Octanforbindelser | |
| NO308794B1 (no) | Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse | |
| TR200000520A2 (tr) | 4-Fenil-piridin türevleri. | |
| LU92154I2 (fr) | Axitinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable | |
| ES2042520T3 (es) | Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo. | |
| ATE211384T1 (de) | Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera | |
| ATE495793T1 (de) | Antitumorzusammensetzungen welche ecteinascidin 743 enthalten | |
| NO942952D0 (no) | 11-benzaldoksin-17 ater, fremgangsmåte for deres fremstilling samt legemiddel inneholdende slike | |
| ES2062011T3 (es) | Derivado de ciclohexano. | |
| ATE283695T1 (de) | Verwendungen und zusammenstellungen von nitratestern als sedativa | |
| DK1110554T3 (da) | Medicinal præparater til behandling af öjensygdomme | |
| DE69322251D1 (de) | Medizinische zusammensetzung | |
| ES2092646T3 (es) | Metanoantracenos como antagonistas de dopamina. | |
| MX9300423A (es) | Derivados heterociclicos. | |
| NL300041I1 (nl) | Versterkingsmiddel voor het antineoplastisch effect en antineoplastisch middel. | |
| DE69522827D1 (de) | Fibrinogen receptor antagonisten mit substituierten b-aminosäurenestern und diese enthaltende pharmazeutische präparate | |
| FI923662A0 (fi) | Terapeutiska medel. | |
| ES2043719T3 (es) | Administracion de farmacos por via percutanea. | |
| UY26329A1 (es) | Antagonistas de los receptores de vitronectina | |
| ES2057053T3 (es) | Compuestos benzoheterociclicos. | |
| ITMI920979A0 (it) | N-acil derivati di aminoalcooli come agenti terapeutici attivi sull'edema neurogenico endoneurale a livello del nervo periferico. | |
| ATE106732T1 (de) | Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung. | |
| ATE169922T1 (de) | Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase | |
| MX9302929A (es) | Derivados de tetrahidro y perhidroisoquinolina y medios terapeuticos que los contienen. | |
| DK1142575T3 (da) | Lægemidler til tör hud |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 354787 Country of ref document: ES |